S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
NASDAQ:ANAB

AnaptysBio (ANAB) Stock Price, News & Analysis

$20.00
-1.47 (-6.85%)
(As of 03:33 PM ET)
Today's Range
$19.79
$21.78
50-Day Range
$20.67
$26.47
52-Week Range
$13.36
$27.50
Volume
264,332 shs
Average Volume
312,021 shs
Market Capitalization
$535.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.22

AnaptysBio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
122.7% Upside
$46.22 Price Target
Short Interest
Bearish
18.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of AnaptysBio in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$3.59 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.25) to ($5.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

Medical Sector

462nd out of 914 stocks

Pharmaceutical Preparations Industry

206th out of 418 stocks

ANAB stock logo

About AnaptysBio Stock (NASDAQ:ANAB)

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Stock Price History

ANAB Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
AnaptysBio (NASDAQ:ANAB) Shares Down 8.2%
AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $22.17
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Unveiling 4 Analyst Insights On AnaptysBio
J.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)
ANAB Mar 2024 20.000 call
AnaptysBio Stock (NASDAQ:ANAB) Insider Trades
See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
117
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$46.22
High Stock Price Target
$80.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+129.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-163,620,000.00
Net Margins
-953.66%
Pretax Margin
-953.68%

Debt

Sales & Book Value

Annual Sales
$17.16 million
Book Value
$3.32 per share

Miscellaneous

Free Float
17,262,000
Market Cap
$539.75 million
Optionable
Optionable
Beta
-0.30

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Daniel R. Faga (Age 44)
    President, CEO & Director
    Comp: $867.12k
  • Mr. Eric J. LoumeauMr. Eric J. Loumeau (Age 61)
    Chief Legal Officer
    Comp: $685.59k
  • Dr. James Newman Topper M.D. (Age 62)
    Ph.D., Advisor
    Comp: $86.5k
  • Dr. Paul F. Lizzul FAAD (Age 49)
    M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
    Comp: $656.36k
  • Mr. Dennis M. Mulroy (Age 69)
    Chief Financial Officer
    Comp: $448.81k
  • Ms. Beth Mueller
    Senior Vice President of Human Resources
  • Dr. Martin Dahl Ph.D.
    Senior Vice President of Research
  • Mr. Benjamin Stone
    Chief Business Officer
  • Mr. Douglas A. Rich M.B.A. (Age 55)
    Senior Vice President of CMC
  • Ms. Monique Da Silva
    Senior Vice President of Corporate Affairs

ANAB Stock Analysis - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANAB shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price target for 2024?

10 brokerages have issued 12 month price objectives for AnaptysBio's shares. Their ANAB share price targets range from $21.00 to $80.00. On average, they anticipate the company's share price to reach $46.22 in the next twelve months. This suggests a possible upside of 122.7% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2024?

AnaptysBio's stock was trading at $21.42 at the beginning of 2024. Since then, ANAB shares have decreased by 3.1% and is now trading at $20.76.
View the best growth stocks for 2024 here
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Monday, March, 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.15. The biotechnology company had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative trailing twelve-month return on equity of 119.42%.

What ETF holds AnaptysBio's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 4,551 shares of ANAB stock, representing 0.91% of its portfolio.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANAB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners